秋水仙碱血药浓度与疗效及不良事件的关系:秋水仙碱预防痛风发作随机临床试验的事后分析
该事后分析基于一项为期12个月、纳入200例痛风患者的随机对照试验,比较低剂量秋水仙碱与安慰剂在起始别嘌醇治疗前6个月的效果并随访6个月。在79例秋水仙碱组患者中,谷浓度或峰浓度与痛风发作预防疗效无关,与秋水仙碱特异性不良事件也无一致关系;尽管合用他汀时浓度升高,但未导致肌肉相关不良事件。作者认为秋水仙碱治疗药物监测在临床实践中价值有限。
要点
- 秋水仙碱谷浓度或峰浓度与痛风发作预防疗效无关。
- 秋水仙碱浓度与秋水仙碱特异性不良事件(胃肠道和肌肉)无一致关系。
- 合用他汀时秋水仙碱浓度升高,但未导致肌肉相关不良事件。
核心结论
- 秋水仙碱谷浓度或峰浓度与痛风发作预防疗效无关。
- 秋水仙碱浓度与秋水仙碱特异性不良事件之间无一致关系。
- 尽管合用他汀时秋水仙碱浓度升高,但未导致肌肉相关不良事件。
- 这些发现表明秋水仙碱治疗药物监测在临床实践中价值有限。
研究设计与样本
- 事后分析使用一项为期12个月、纳入200例痛风患者的随机对照试验数据,该试验比较低剂量秋水仙碱与安慰剂用于起始别嘌醇治疗的前6个月,并进一步随访6个月。
- 在第3个月于给药后30至80分钟(假定峰浓度)及给药前(谷浓度)测量秋水仙碱稳态血浆浓度,并在第0、3、6个月测量肌酸激酶(CK)水平。
- 每月收集自我报告的痛风发作、不良事件和严重不良事件。
主要发现
- 秋水仙碱组79例参与者有峰浓度和谷浓度数据。
- 多变量分析显示,服用他汀及非毛利和非太平洋族裔与较高谷浓度独立相关,年龄大于60岁与较高峰浓度独立相关。
- 在第4至6个月之间发生任何不良事件者,其谷浓度和峰浓度均显著更高。
- 秋水仙碱浓度与秋水仙碱特异性不良事件(胃肠道和肌肉)或秋水仙碱治疗患者的CK变化之间无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objective was to examine the relationship between colchicine plasma concentrations and clinical and demographic factors and to determine the relationship between colchicine concentrations and colchicine efficacy and colchicine-specific adverse events. METHODS: Post hoc analyses were undertaken using data from a 12-month randomized controlled trial involving 200 people with gout that compared low-dose colchicine to placebo for the first six months while starting allopurinol, with a further six-month follow-up. Steady-state colchicine plasma concentrations were measured 30 to 80 minutes post dose (assumed peak) and just before the dose (trough) at month three, and creatine kinase (CK) levels were measured at months zero, three, and six. Self-reported gout flares, adverse events, and serious adverse events were collected monthly. RESULTS: Peak and trough colchicine concentrations were available for 79 participants in the colchicine arm. Multivariable analysis showed that those taking a statin and non-Māori and non-Pacific ethnicity were independently associated with higher trough concentrations, and age older than 60 years was independently associated with higher peak concentrations. Trough and peak colchicine concentrations were significantly higher in those who had any adverse event between months four and six. However, there was no association between colchicine concentrations and colchicine-specific adverse events (gastrointestinal and muscle) or with CK changes in the colchicine-treated patients. CONCLUSION: Trough or peak colchicine concentrations are not associated with gout flare prophylaxis efficacy. There is no consistent relationship between colchicine concentrations and colchicine-specific adverse events. Although colchicine concentrations increase with concomitant statin use, this does not result in muscle-related adverse events. These findings indicate that colchicine therapeutic drug monitoring is of limited value in clinical practice.
引用
- Stamp LK, Horne A, Mihov B, et al. Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis. Arthritis Care Res (Hoboken). 2025. PMID: 40223442. doi:10.1002/acr.25548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。